/NOT FOR DISTRIBUTION TO UNITED
STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES. ANY FAILURE TO
COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF
UNITED STATES SECURITIES LAWS/
TORONTO, Aug. 7, 2020 /CNW/ - Avicanna Inc.
("Avicanna" or the "Company") (TSX: AVCN) (OTCQX:
AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products, is pleased to announce that it has
scheduled a conference call on Monday,
August 17, 2020 at 9:00AM Eastern
Time to discuss the results for its fiscal second quarter
ended June 30, 2020. Aras Azadian, Chief Executive Officer and
Davender Sohi, Chief Financial
Officer, will host the call and a question and answer period. The
Company will report its financial results for the second quarter
after the close of markets on Friday, August
14, 2020.
Conference Call Details
DATE:
|
August 17,
2020
|
TIME:
|
9:00 AM Eastern
Time
|
|
|
CONFIRMATION
#:
|
64751998
|
|
|
TORONTO:
|
416-764-8659
|
NORTH AMERICAN TOLL
FREE:
|
1-888-664-6392
|
GERMANY TOLL
FREE:
|
08007240293
|
COLOMBIA TOLL
FREE:
|
018005184036
|
|
|
REPLAY
TORONTO:
|
416-764-8677
|
REPLAY NORTH
AMERICA:
|
1-888-390-0541
|
REPLAY ENTRY
CODE:
|
751998#
|
REPLAY EXPIRATION
DATE:
|
August 24,
2020
|
About Avicanna Inc.
Avicanna is an Ontario, Canada
based corporation focused on the development, manufacturing, and
commercialization of plant-derived cannabinoid-based products
through its two main business segments, cultivation and research
and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S.
and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's
cultivation activities. These two companies are licensed to
cultivate and process cannabis for the production of cannabis
extracts and purified cannabinoids including cannabidiol (CBD) and
tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily
conducted out of Canada at its
headquarters in the Johnson & Johnson Innovation Centre, JLABS
@ Toronto. Avicanna's scientific
team develops products, and Avicanna has also engaged the services
of researchers at the Leslie Dan Faculty of Pharmacy at the
University of Toronto for the purpose
of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities
are focused on the development of its key products, including
plant-derived cannabinoid pharmaceuticals, phyto-therapeutics,
derma-cosmetics, and Extracts (defined as plant-derived cannabinoid
extracts and purified cannabinoids, including distillates and
isolates), with a goal of eventually having these products
manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna,
visit www.avicanna.com, call 1-647-243-5283, or contact
Setu Purohit, President by email
at info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and
Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These forward-looking statements are only
predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions, estimates and
assumptions of management in light of management's experience and
perception of historical trends, current conditions and expected
developments at the date the statements are made, such as current
and future market conditions, the current and future regulatory
environment and future approvals and permits. Forward-looking
statements are subject to a variety of risks, uncertainties and
other factors that management believes to be relevant and
reasonable in the circumstances could cause actual events, results,
level of activity, performance, prospects, opportunities or
achievements to differ materially from those projected in the
forward-looking statements, including general business and economic
conditions, changes in laws and regulations, product demand,
changes in prices of required commodities, competition, the effects
of and responses to the COVID-19 pandemic and other risks,
uncertainties and factors set out under the heading "Risk Factors"
in the Company's annual information form dated April 15, 2020 (the "AIF") and filed with
Canadian securities regulators available on the Company's issuer
profile on SEDAR at www.sedar.com. The Company cautions that the
list of risks, uncertainties and other factors described in the AIF
is not exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
laws.
SOURCE Avicanna Inc.